Iqirvo (elafibranor) has been conditionally approved in the European Union to treat adults with primary biliary cholangitis (PBC),…
Articles by Margarida Maia, PhD
Abnormal levels of certain fatty molecules, or lipids, in the blood appear to increase the risk of intrahepatic cholestasis…
Chroma Medicine’s investigational one-time treatment CRMA-1001 for chronic hepatitis B brought levels of a key hepatitis B virus (HBV)…
Cholestasis, where the flow of the digestive fluid bile from the liver to the intestines slows or stalls, is…
A triple treatment combination adding fibrates — a type of medication that has shown promise in primary biliary cholangitis…
Having persistently high blood levels of bilirubin, a marker of liver damage, a year after undergoing a corrective liver surgery…
The World Health Organization (WHO) has prequalified the first self-test kit to detect the hepatitis C virus (HCV)…
Livmarli (maralixibat), an oral medication from Mirum Pharmaceuticals, is now approved in the European Union to treat progressive…
A type of cell death called ferroptosis contributes to metabolic dysfunction-associated steatotic liver disease (MASLD), a form of fatty…
Women who develop a subtype of intrahepatic cholestasis of pregnancy (ICP) marked by jaundice — a yellowing of the…